eccogene glp-1 Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China AstraZeneca licenses Eccogene's oral GLP-1

Whether youre preparing for a special event or just want to maintain a glowing complexion year-round, IV therapy can help you achieve long-lasting skin radiance

Informational only

In db/db diabetic mice, BCAA supplementation led to elevated BCKA levels, promoting excessive macrophage activation

Tirzepatide does not directly damage hair follicles, but some people experience temporary hair shedding during rapid weight loss

(Note: no poisons are currently listed in this schedule in the SUSDP.) Schedule 2 Poisons for therapeutic use that should be available to the public only from pharmacies, or if there is no pharmacy service available, from persons licensed to sell Schedule 2 poisons

Scientific References Incretin hormones and type 2 diabetes